Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation

Clin Nucl Med. 2016 Mar;41(3):204-6. doi: 10.1097/RLU.0000000000000973.

Abstract

A 22-year-old woman with rapidly progressing metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation, who recurred after neoadjuvant chemotherapy, was found to be MIBG avid. She was treated with 2 I-MIBG treatments and concurrent sunitinib, achieving a complete response. She was in full remission for 9 months before developing bone metastases.

Publication types

  • Case Reports

MeSH terms

  • 3-Iodobenzylguanidine / administration & dosage
  • 3-Iodobenzylguanidine / therapeutic use*
  • Adrenal Gland Neoplasms / genetics
  • Adrenal Gland Neoplasms / pathology
  • Adrenal Gland Neoplasms / therapy*
  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy
  • Chemoradiotherapy
  • Female
  • Humans
  • Indoles / administration & dosage
  • Indoles / therapeutic use*
  • Mutation
  • Pheochromocytoma / genetics
  • Pheochromocytoma / pathology
  • Pheochromocytoma / therapy*
  • Pyrroles / administration & dosage
  • Pyrroles / therapeutic use*
  • Remission Induction
  • Succinate Dehydrogenase / genetics*
  • Sunitinib

Substances

  • Indoles
  • Pyrroles
  • 3-Iodobenzylguanidine
  • SDHB protein, human
  • Succinate Dehydrogenase
  • Sunitinib